324 related articles for article (PubMed ID: 19890606)
1. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
Kramer K; Kushner BH; Modak S; Pandit-Taskar N; Smith-Jones P; Zanzonico P; Humm JL; Xu H; Wolden SL; Souweidane MM; Larson SM; Cheung NK
J Neurooncol; 2010 May; 97(3):409-18. PubMed ID: 19890606
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.
Kramer K; Pandit-Taskar N; Zanzonico P; Wolden SL; Humm JL; DeSelm C; Souweidane MM; Lewis JS; Cheung NK
J Neurooncol; 2015 Jun; 123(2):245-9. PubMed ID: 25944385
[TBL] [Abstract][Full Text] [Related]
3. Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma.
Luo LY; Kramer K; Cheung NV; Kushner BH; Modak S; Basu EM; Roberts SS; Wolden SL
Pediatr Blood Cancer; 2020 Sep; 67(9):e28364. PubMed ID: 32608559
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of pediatric patients receiving multimodality treatment of second central nervous system relapse of neuroblastoma.
Tringale KR; Wolden SL; Casey DL; Kushner BH; Luo L; Pandit-Taskar N; Souweidane M; Cheung NV; Modak S; Basu EM; Kramer K
Pediatr Blood Cancer; 2023 Feb; 70(2):e30075. PubMed ID: 36349892
[TBL] [Abstract][Full Text] [Related]
5. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma.
Croog VJ; Kramer K; Cheung NK; Kushner BH; Modak S; Souweidane MM; Wolden SL
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):849-54. PubMed ID: 20207502
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of intraventricular
Kramer K; Pandit-Taskar N; Kushner BH; Zanzonico P; Humm JL; Tomlinson U; Donzelli M; Wolden SL; Haque S; Dunkel I; Souweidane MM; Greenfield JP; Tickoo S; Lewis JS; Lyashchenko SK; Carrasquillo JA; Chu B; Horan C; Larson SM; Cheung NV; Modak S
J Hematol Oncol; 2022 Nov; 15(1):165. PubMed ID: 36371226
[TBL] [Abstract][Full Text] [Related]
7. Multimodality treatment for recurrent neuroblastoma in the central nervous system.
Desai AV; Elmuti L; Cahaney C; De Guzman RM; Streby KA; Cohn SL
Pediatr Blood Cancer; 2023 Apr; 70(4):e30227. PubMed ID: 36720647
[TBL] [Abstract][Full Text] [Related]
8. Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging.
Kellie SJ; Hayes FA; Bowman L; Kovnar EH; Langston J; Jenkins JJ; Pao WJ; Ducos R; Green AA
Cancer; 1991 Nov; 68(9):1999-2006. PubMed ID: 1913549
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of radioimmunotherapy with intraventricular
Kramer K; Pandit-Taskar N; Humm JL; Zanzonico PB; Haque S; Dunkel IJ; Wolden SL; Donzelli M; Goldman DA; Lewis JS; Lyashchenko SK; Khakoo Y; Carrasquillo JA; Souweidane MM; Greenfield JP; Lyden D; De Braganca KD; Gilheeney SW; Larson SM; Cheung NV
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28940863
[TBL] [Abstract][Full Text] [Related]
11. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia.
Ribeiro RC; Rivera GK; Hudson M; Mulhern RK; Hancock ML; Kun L; Mahmoud H; Sandlund JT; Crist WM; Pui CH
J Clin Oncol; 1995 Feb; 13(2):333-8. PubMed ID: 7844594
[TBL] [Abstract][Full Text] [Related]
12. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
[TBL] [Abstract][Full Text] [Related]
13. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
14. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy.
Kushner BH; Kramer K; LaQuaglia MP; Cheung NK
J Pediatr Hematol Oncol; 2003 Jul; 25(7):515-9. PubMed ID: 12847316
[TBL] [Abstract][Full Text] [Related]
15. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
17. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
Kushner BH; Kramer K; Modak S; Cheung NK
J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies.
Kramer K; Smith M; Souweidane MM
Pediatr Blood Cancer; 2014 Sep; 61(9):1590-2. PubMed ID: 24777835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
